Arturo Soto-Matos

Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i>-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

Cristina Cruz, Alba Llop‐Guevara, Judy E. Garber et al. · Journal of Clinical Oncology · 2018 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies

Patrick Schöffski, Herlinde Dumez, Rita Ruijter et al. · Cancer Chemotherapy and Pharmacology · 2011 · 38 citations · Full text

Pharmacy, Oncology, Pharmacology +10

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

Gerald J. Fetterly, Joel Owen, Kim Stuyckens et al. · Cancer Chemotherapy and Pharmacology · 2007 · 31 citations

Medicine, Pharmacokinetics, Pharmacology +12

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin

Federica Grosso, Maurizio D’Incalci, Mirela Cartoafa et al. · Cancer Chemotherapy and Pharmacology · 2012 · 28 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis

Claudia Lebedinsky, Javier Gómez, Youn C. Park et al. · Cancer Chemotherapy and Pharmacology · 2011 · 27 citations

Medicine, Cardiology, Interventional Cardiology +12